These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30146959)

  • 41. Promoting Antibacterial Drug Development: Select Policies and Challenges.
    Sertkaya A; Jessup A; Wong HH
    Appl Health Econ Health Policy; 2017 Feb; 15(1):113-118. PubMed ID: 27601239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Innovation of novel antibiotics: an economic perspective.
    McKellar MR; Fendrick AM
    Clin Infect Dis; 2014 Oct; 59 Suppl 3():S104-7. PubMed ID: 25261536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A three-step plan for antibiotics.
    Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
    [No Abstract]   [Full Text] [Related]  

  • 45. Report urges controversial 'delinkage' to foster new antibiotics.
    Holmes D
    Nat Med; 2014 Apr; 20(4):320. PubMed ID: 24710363
    [No Abstract]   [Full Text] [Related]  

  • 46. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The global need for effective antibiotics: challenges and recent advances.
    Högberg LD; Heddini A; Cars O
    Trends Pharmacol Sci; 2010 Nov; 31(11):509-15. PubMed ID: 20843562
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K; Rex JH
    Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.
    Renwick MJ; Brogan DM; Mossialos E
    J Antibiot (Tokyo); 2016 Feb; 69(2):73-88. PubMed ID: 26464014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020.
    Infectious Diseases Society of America
    Clin Infect Dis; 2010 Apr; 50(8):1081-3. PubMed ID: 20214473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preserving the 'commons': addressing the sustainable use of antibiotics through an economic lens.
    Morel CM; Edwards SE; Harbarth S
    Clin Microbiol Infect; 2017 Oct; 23(10):718-722. PubMed ID: 28811243
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Economic Conundrum for Antibacterial Drugs.
    Shlaes DM
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance diagnosis and the changing economics of antibiotic discovery.
    McAdams D
    Ann N Y Acad Sci; 2017 Jan; 1388(1):18-25. PubMed ID: 28072904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Commentary: How to encourage more diagnostics for infectious diseases.
    Powers JH
    BMJ; 2016 Sep; 354():i4744. PubMed ID: 27604999
    [No Abstract]   [Full Text] [Related]  

  • 60. Incentives for developing new antibiotics or antimicrobial strategies.
    Dahle UR; Petersen FC
    BMJ; 2013 Apr; 346():f2136. PubMed ID: 23568793
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.